Biosimilars articles Samsung Biopeis’ Keytruda biosimilar enters Phase III trials Samsung Biopeis has initiated a Phase III trial for its proposed Keytruda (pembrolizumab) biosimilar referenced candidate SB27. The... Related Articles In News From Clinical Trials Arena 2024-04-05T14:03:25.000Z